The Bob Harrington Show

Drs Harrington and Gibson review their picks for the top cardiology trials of 2024 and look ahead to 2025, particularly what health topics may be prioritized by the new administration. This podcast is intended for healthcare professionals only. To read a transcript or to comment https://www.medscape.com/author/bob-harrington Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (REDUCE AMI) https://www.nejm.org/doi/abs/10.1056/NEJMoa2401479 Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD) https://doi.org/10.1056/nejmoa2412006 Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis EARLY TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 Asundexian versus Apixaban in Patients with Atrial Fibrillation (OCEANIC-AF) https://doi.org/10.1056/NEJMoa2407105 In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat? https://www.jacc.org/doi/10.1016/j.jacc.2024.10.105 Preventive percutaneous coronary intervention versus